HER2 Status Determination via CRIP1 Protein Variant Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the HER2 expression status in breast cancer tissues, such as immunohistochemistry and fluorescence in situ hybridization, are inadequate for accurately predicting patient response to trastuzumab and prognosis, as they lack sensitivity and specificity, and do not effectively utilize protein-level biomarkers like CRIP1 for therapeutic decision-making.
Innovation Solution
The use of Matrix-Assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS) to measure and compare the amounts of CRIP1 protein variants with specific molecular weights in breast cancer tissues, allowing for the direct analysis of protein patterns and classification of HER2-positive and HER2-negative samples, thereby predicting drug response and prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunohistochemistry or fluorescence in situ hybridization is used to determine HER2 expression status, then the diagnostic process can be performed, but the sensitivity and specificity are insufficient for accurately predicting patient response to trastuzumab and prognosis
Solution Approach 1:
The invention changes the measurement parameter from detecting HER2 protein expression levels (immunohistochemistry) or gene amplification (FISH) to detecting specific CRIP1 protein variants with molecular weights of 8419, 8435, 8450, or 8465 atomic mass units. This parameter change enables more accurate prediction of trastuzumab response and patient prognosis, resolving the contradiction between diagnostic capability and predictive reliability
Solution Approach 2:
The invention replaces conventional immunohistochemical or FISH-based detection methods with mass spectrometry-based detection of CRIP1 protein variants. This substitution provides superior sensitivity and specificity, enabling accurate classification of HER2-positive and HER2-negative breast cancers and reliable prediction of therapeutic response
2Adaptability or versatility
If conventional HER2 testing methods are used, then diagnostic results can be obtained, but they cannot effectively utilize protein-level biomarkers like CRIP1 for therapeutic decision-making
Solution Approach 1:
The invention introduces CRIP1 protein variants as intermediary biomarkers that mediate between HER2 expression status and trastuzumab response prediction. These specific protein variants (8419, 8435, 8450, or 8465 atomic mass units) serve as reliable indicators that bridge the gap between conventional HER2 testing and therapeutic outcome prediction, enabling effective utilization of protein-level information for clinical decision-making
3Measurement precision
If mass spectrometry is used to detect CRIP1 protein variants, then accurate classification and prediction can be achieved, but the method must be validated to ensure reliability
Solution Approach 1:
The invention implements a feedback mechanism by comparing CRIP1 protein variant levels in breast cancer tissues with known HER2 status and clinical outcomes. The method has been validated by comparing results with established HER2 testing methods and correlating with patient response to trastuzumab and prognosis, thereby ensuring the reliability of the mass spectrometry-based classification approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MALDI IMS provides accurate classification of HER2 expression status with high sensitivity and specificity, enabling reliable prediction of patient prognosis and response to therapy, and can be applied to small tumor tissue specimens, potentially improving clinical management of breast cancer.
Implementation Method 1
The use of Matrix-Assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS) to measure and compare the amounts of CRIP1 protein variants
Data Source
Figure 1A~1B
Figure 1C-1~1C-2
Figure 1C-3~1C-4
AI summary
The invention is related to determining the expression status of the human epidermal growth factor receptor 2 (HER2), diagnosing cancer and predicting the response of a cancer patient to a drug or predicting the prognosis of a cancer patient. The method according to the invention comprises measuring amounts of two or more proteins in a sample, wherein the two or more proteins have substantially one of following molecular weights 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, or measuring amounts of at least one of the human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and of proteolytic digestion products thereof in the sample.